Keywords: Merck KGaA, Erbitux, EMEA, Cardiac risks

Merck KGaA dips after EU regulator calls for review of Erbitux

Article | 25 March 2010

Print This

German drug major Merck KGaA is reviewing cardiac risks of its oncology drug Erbitux (cetuximab) in several types of cancer ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in